BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ADR-002K readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ADR-002K\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07192211-612@assetmemo.bio
DTSTAMP:20261121T005833Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:ADR-002K: Phase 2 readout est. (NCT07192211)
DESCRIPTION:ADR-002K\, phase 2\, Heart Failure.\nStudy: Exploratory Study o
 f ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Unde
 rgo CABG\nEstimated primary completion: 30 September 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/adr-002k#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07192211
URL:https://assetmemo.bio/drug/adr-002k#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
